lundi 16 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· April 11, 2026

Is It Too Late To Consider AstraZeneca (LSE:AZN) After Its 54.8% One-Year Surge?

View original at finance.yahoo.com
“For AstraZeneca, the latest twelve month Free Cash Flow (FCF) is about US$9.49b.”
Verbatim excerpt from the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AstraZeneca has a valuation score of 3 out of 6

    60% confidence
  • The DCF model arrives at an estimated intrinsic value of US$238.68 per share for AstraZeneca

    60% confidence
  • AstraZeneca's DCF analysis suggests the stock is undervalued by 36.2%

    60% confidence

Data points we hold from this source

AstraZeneca AB · stock return 30day5.2 percent
AstraZeneca AB · stock return 1year54.8 percent
AstraZeneca AB · free cash flow9.49 USD
AstraZeneca AB · stock return ytd12.1 percent
AstraZeneca AB · projected free cash flow20.16 USD
AstraZeneca AB · valuation score3 out_of_6
AstraZeneca AB · intrinsic value dcf238.68 USD
AstraZeneca AB · stock return 7day-0.6 percent
Is It Too Late To Consider AstraZeneca (LSE:AZN) After Its 54.8% One-Year Surge?: Source | Via News | fr.via.news